Innovent Biologics Placement - Second for the Month, Stock Has Doubled but Momentum Is Strong
Innovent Biologics Inc (1801 HK) aims to raise around US$500m for R&D and marketing. In this note, we talk about the deal dynamics.
617 Views
Sichuan Kelun-Biotech Biopharm (6990.HK) Placement - Thoughts The Pipeline and Valuation Outlook
Kelun Bio's HK$331.8/share Placing price is expensive.Valuation should be higher than Akeso.Buy when valuation falls in US$2.5-5.25 billion...
510 Views
Kelun-Biotech Placement - Recent Run-Up Makes Its Tricky
Kelun-Biotech Biopharmaceutical Co (Kelun) is looking to raise up to US$200m from a primary placement. In this note, we will talk about the...
523 Views
Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed
WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...
586 Views
Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well
WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.
806 Views